Addressing a difficile problem

Researchers in Ireland and Canada have identified a bacterial peptide with narrow-spectrum antimicrobial activity against Clostridium difficile.1 The peptide, which is licensed to Alimentary Health Ltd.,could reduce the risk of disease recurrence compared with that of broad-spectrum antibiotic treatment because it spares the normal gut flora that helps limit C. difficile growth.

C. difficile is a Gram-positive opportunistic bacterium that can cause gastrointestinal conditions such as diarrhea and pseudomembranous colitis after a patient has been treated for unrelated bacterial infections.

Antibiotics can unbalance normal gut flora, thus creating an environment that could be conducive to C. difficile growth. Even if the

Read the full 1006 word article

How to gain access

Continue reading with a
two-week free trial.